RA is characterized by synovial inflammation, the production of autoantibodies such as rheumatoid factor (RF) and anti-citrullinated protein antibody,[1] raised C-reactive protein levels, and an increased erythrocyte sedimentation rate.[5] The first-line therapy for RA is methotrexate (MTX) which is highly effective as monotherapy or when combined with other disease-modifying antirheumatic drugs (DMARDs) or biological treatments.[6]. Here, CRP is linked to rheumatoid arthritis.